Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding (publ) (ticker:VICO) announces that an application to start a Phase IIa study with C21 in patients suffering from Idiopathic Pulmonary Fibrosis has been submitted to the authorities.

Vicore Pharma announces that an application has been sent to the British medicines authority, MHRA to start a Phase IIa study with C21 in patients with Idiopathic Pulmonary Fibrosis (IPF). We are expecting feedback on the application within 60 days which is customary on applications to the MHRA.

 “We have now reached an important milestone with the submitted application for the Phase IIa study. My colleagues have worked hard and dedicated with this submission. Now we await the evaluation of the application in cooperation with with our clinical partners” says Per Jansson, CEO Vicore Pharma.

For further information, please contact
Per Jansson, CEO
M: +46 709 17 47 46 or e-mail: per.jansson@vicorepharma.com

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 14.00 CET on December 22, 2017

About Vicore Pharma Holding
Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see  www.vicorepharma.com